| gap-pubmed-20260410- | What determines the threshold between normal (2-10 repeats) and pathogenic (hund | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do C9orf72 repeat expansions mechanistically disrupt multiple cellular proce | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which of the three proposed C9orf72 mechanisms (haploinsufficiency, RNA toxicity | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the eight upregulated genes mechanistically cause telencephalic midline d | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | Why do only 66 of 806 SIX3 target genes show expression changes in Asxl1-deficie | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What is the molecular mechanism by which ASXL1-SIX3 interaction regulates chroma | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What molecular mechanisms govern the feedforward loop regulating PINK1-Parkin mi | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does PINK1/Parkin-mediated mitophagy paradoxically promote cancer cell survi | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Under what conditions does microglial depletion provide therapeutic benefit vers | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific mechanisms by which microglia contribute to neuronal devel | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do lysosomal hydrolase redistributions lead to neurotoxic amyloid peptide ov | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ceramide accumulation mechanistically compromise endocytic trafficking | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the pathophysiological consequences of endosomal/lysosomal changes in s | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does NOX4-mediated ferroptosis in diabetic keratopathy relate to ferroptotic | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the bidirectional positive feedback loop betw | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the functional roles of TREM2+ microglial subsets identified in OxPC le | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do OxPCs transition from oxidative stress markers to active neurodegenerativ | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms enable microglia to neutralize OxPC-mediated neurodege | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the specificity and efficiency of astrocyte-to-neuron mitochondr | open | 0.74 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | Why does seizure-induced astrocytic LCN2 upregulation counteract the protective | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does LCN2/NLRP3 signaling mechanistically control both pyroptosis and TNT fo | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What downstream mechanisms link Axl/Rac1 activation to enhanced microglia effero | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does Gas6 but not ProS1 promote microglia efferocytosis despite both being T | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do timing and dosing parameters affect cell-specific responses in multi-drug | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What biomarkers can effectively stratify patients for autophagy-targeted combina | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do benzimidazole derivatives enhance JIP4-TRPML1 lysosomal fusion pathways i | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does neuroglobin simultaneously inhibit Wnt/β-catenin while enhancing NFκB a | open | 0.79 | 0.00 | 2026-04-10 | 0 | | cell-signaling |
| gap-pubmed-20260410- | What is the molecular mechanism by which neuroglobin promotes Dvl1 proteasomal d | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroprotection |
| gap-pubmed-20260410- | Why does acetylated tau preferentially utilize macroautophagy and endosomal micr | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does CMA dysfunction mechanistically enhance cell-to-cell propagation of pat | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms cause acetylated tau to specifically inhibit chaperone | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does rapid neuronal modulation via DREADDs affect synaptic plasticity and ci | open | 0.75 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What are the long-term safety and off-target effects of deschloroclozapine in ch | open | 0.78 | 0.00 | 2026-04-10 | 0 | | chemogenetics |
| gap-pubmed-20260410- | What determines whether cGAS-STING activation is neuroprotective versus neurotox | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does cGAMP activate TREM2-DAP10-PI3K signaling independently of canonical ST | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do NTRK2 gene-gene interactions contribute to suicidal behavior risk? | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neuropsychiatry |
| gap-pubmed-20260410- | Why does NTRK2 show minimal association with suicidality despite being the prima | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuropsychiatry |
| gap-pubmed-20260410- | What are the mechanistic relationships between preclinical biomarkers across dif | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do lifestyle factors mechanistically modulate genetic risk variants identifi | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do only half of TBEV-infected patients progress to the neurological phase? | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What objective biomarkers can assess long-term neurological sequelae after TBEV | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms underlie the characteristic biphasic disease course in TBEV ence | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does AQP4 inhibition mechanistically reverse the no-reflow phenomenon in isc | open | 0.82 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | What molecular mechanisms explain why systemic AQP4 inhibition impairs glymphati | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | Does CK1BP's anti-aggregation effect extend to other disease-relevant proteins b | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does CK1BP reduce overall α-synuclein protein levels - through decreased syn | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the molecular mechanism by which CK1BP reduces α-synuclein levels indepe | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the context-dependent switch between destructive and regenerativ | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do myelin-specific T cells specifically enhance calretinergic fiber sproutin | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms enable myelin-specific T cells to stimulate oligodendr | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |